Scarica l'app Stockscreener
10.05
0.59%
-0.06
Dopo l'orario di chiusura:
10.06
0.010
+0.10%
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Why ARS Pharmaceuticals Inc. stock could rally in 2025Quarterly Profit Report & Risk Managed Investment Entry Signals - newser.com
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Treasury Yields & Smart Investment Allocation Insights - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this weekQuarterly Profit Summary & Safe Capital Growth Stock Tips - newser.com
Sentiment analysis tools applied to ARS Pharmaceuticals Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatility2025 Dividend Review & Free Expert Verified Stock Movement Alerts - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelinePortfolio Risk Report & High Return Trade Opportunity Guides - newser.com
Price action breakdown for ARS Pharmaceuticals Inc.Weekly Trade Summary & Community Consensus Trade Signals - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
ARS Pharmaceuticals (SPRY): Assessing Valuation After European Patent Win Secures Neffy Exclusivity Through 2039 - Sahm
How to track smart money flows in ARS Pharmaceuticals Inc.Market Trend Summary & Accurate Trade Setup Notifications - newser.com
ARS Pharmaceuticals (SPRY) Is Up 9.8% After Securing $250M Loan and European Patent Win – Has the Bull Case Changed? - Sahm
Epi Spray Maker Urges FDA to Require More Study of Epi Film - Allergic Living
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Hits Day High with 7.55% Surge to $11.11 - Markets Mojo
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe By Investing.com - Investing.com Australia
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Uncovering a 205% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Janney Montgomery Scott LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
1.84%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):